Phase 3 Epilepsy Trial, Recruiting NCT06579573 Sponsor: Ono Pharmaceutical Co., Ltd. Condition: Epilepsy
Back to Epilepsy

Phase 3 Epilepsy Trial, Recruiting

NCT06579573
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are Japanese, aged 12 years or older, regardless of gender
  • You have been diagnosed with a type of epilepsy called "Primary Generalized Tonic-Clonic (PGTC) seizures" linked to a condition known as idiopathic generalized epilepsy
  • You have had at least 5 of these tonic-clonic seizures over a 12-week period
  • You are currently taking between 1 and 3 anti-seizure medications at stable, consistent doses

Who may not be able to join:

  • You have had a severe, prolonged seizure episode (called status epilepticus) that required a hospital stay within the past 15 months
  • Your seizures happen in clusters where it is not possible to count or identify them individually
  • You have a history of seizures that are not caused by epilepsy, including seizures linked to psychological causes
  • You have also been diagnosed with a different type of seizure disorder called "Partial Onset Seizures"
  • You have a history of a serious allergic or skin reaction to a medication — such as Stevens-Johnson syndrome, toxic skin reactions, or a severe drug reaction involving your immune system — that required a hospital stay

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Project Leader, Ono Pharmaceutical Co., Ltd.

Phone: +18665877745(Toll-Free)

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Ono Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
12 July 2022
Est. completion
31 January 2027

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Percentage Change in generalized tonic-clonic (PGTC) seizure frequency per 28-Day Interval

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov